Abstract

Abstract Bone marrow-derived mesenchymal stem cells (MSCs) are reported to migrate to tumor stroma as well as injured tissue. We reported recently that, in an orthotopic nude mice model of colon cancer, MSCs traveled to tumor stroma, where they differentiated into carcinoma-associated fibroblasts (CAF)-like cells. We have also found that CAFs express platelet-derived growth factor receptor (PDGFR) at a high level and that imatinib therapy targeting PDGFR in CAFs combined with administration of a cytotoxic drug significantly inhibits growth and metastasis of human colon cancer. These findings led us to examine whether the tumor promoting effect of MSCs is impaired by blockade of PDGFR signaling achieved with imatinib. KM12SM colon cancer cells alone or KM12SM cells mixed with MSCs in a 1:2 ratio were transplanted into the cecal wall of nude mice. Orthotopic transplantation of KM12SM cells mixed with MSCs, in comparison to transplantation of KM12SM cells alone, resulted in tumors of greater weight. The survival rate was significantly lower in the mixed-cell group. Co-injection of MSCs with tumor cells promotes tumor growth and metastasis of colon cancer by enhancing angiogenesis and tumor migration and invasion and by inhibiting tumor cell apoptosis. When tumor bearing animals were treated with imatinib (by gavage once daily at 50 mg/kg for 35 days), there was no significant increase in primary tumor volume or number of metastases with the KM12SM+MSC xenograft and the lower survival rate in the mixed-cell group was prolonged by the treatment. Moreover, migratory ability of MSCs to tumor stroma was impaired, and MSCs surviving in the tumor microenvironment were significantly decreased. In in vitro experiments, treatment with imatinib inhibited migration and proliferation of MSCs. Our data suggest that blockade of PDGFR signaling pathways influences the interaction between bone marrow-derived MSCs and tumor cells in the tumor microenvironment and, hence, inhibits the progressive growth of colon cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 519. doi:10.1158/1538-7445.AM2011-519

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call